A Phase 1/2 interventional study of Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks and Ropivacaine with low, non weight based Dexamethasone additive in Postoperative Pain, Nausea and Vomiting, Postoperative and Dizziness, sponsored by University of Arizona. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by University of Arizona · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies testing dexamethasone in Pain, Postoperative — 27 open to participants now, 31 under way, 2 of them phase 3. Dexamethasone · Pain, Postoperative.
Among the 149 studies testing dexamethasone in Pain, Postoperative, this one is the 53rd largest by planned enrollment, is one of 11 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 17 of the 30 other live ones, and was the 123rd registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →27 of the 149 studies testing dexamethasone in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 50–70
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–79
Marmara University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Oman Ministry of Health · Sites in Oman
Ages 21–80
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 19 · Phase 4 75
First in 2005; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 88 across the 149 interventional studies. Of the 96 that completed or were terminated, 22 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 149 have an industry lead sponsor. The 10 most frequent:
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
University of Arizona has 4 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
11 of the studies testing dexamethasone in Pain, Postoperative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07795281Gaziantep City HospitalIntravenous Dexamethasone Added to Dexmedetomidine After Superior Trunk Block | 2026-12 |
| NCT07380139Ain Shams UniversityDexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain | 2026-12-01 |
| NCT07672873Marmara UniversityLocal Dexamethasone Administration in Symptomatic Irreversible Pulpitis | 2026-12-15 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 149 studies testing dexamethasone in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to improve upon the standard practice of utilizing nerve blocks to enhance the satisfaction of patients undergoing shoulder, or foot and ankle surgery regarding their quality of pain control, the duration of their nerve blocks, as well as the avoidance of opioid medications and subsequently their undesirable side effects. The researchers hypothesize that dexmedetomidine and dexamethasone (Dex-Dex) will work synergistically as adjuncts in a low, non-weight based formula. This would allow the investigators to improve patient satisfaction by providing them with a superior means of pain control that is longer in duration with a decreased probability of unwanted side effects.
The proposed clinical study will be a prospective, randomized control trial.
The standard practice for anesthesia in non-weight-bearing orthopedic foot and ankle surgery is to offer the patient popliteal (sciatic nerve) and saphenous (distal branch of femoral nerve) peripheral nerve blocks for postoperative pain control to minimize opioid requirements. Similarly, supraclavicular nerve blocks that decrease painful stimuli transmission through the brachial plexus are offered to patients undergoing shoulder joint procedures. For these peripheral nerve blocks, it is routine to use dexamethasone (glucocorticoid) as an additive in the local anesthetic injection which can prolong the local anesthetic effect of the blocks by 4-8 hours with minimal side effects observed and no dose-response relationship with perineural injection doses of 4, 8, 10, and 12mg. Though the precise mechanism of action has not been fully understood, it is largely believed that perineural injection of dexamethasone increases the effects of local anesthetics at least in part due to vasoconstriction.
Current literature suggests that 1-2 mcg/kg of dexmedetomidine will also prolong the peripheral nerve blocks but consistent utilization thus far has been limited by side-effects of higher, more efficacious doses. The potential dose-dependent side effects associated with the use of perineural dexmedetomidine include bradycardia, hypotension, and excessive sedation. There are minimal to no side-effects observed when perineural dexmedetomidine doses are kept below 1 mcg/kg. However, its effects on prolonging nerve blocks are not significant until the dose is increased to 1.5 mcg/kg where the nerve block is extended roughly 4-8 hours, similar to using dexamethasone as an adjunct. At doses greater than 2 mcg/kg, however, the nerve block can last up to 2-3 days but at the tradeoff of increased perioperative bradycardia and hypotension from presumed systemic absorption and dexmedetomidine's highly selective α2 agonist effects. Another study showed that when a low, non-weight-based dose of 50 mcg of dexmedetomidine was used in adults weighing over 50 kg, the duration of analgesia was improved, but its effects were less than 8 mg of dexamethasone as an adjunct, and the improvement of the duration of blockade at this low dose of dexmedetomidine was not significant. When both dexamethasone and dexmedetomidine were utilized as intravenous adjuncts administered at the time of performing the nerve blocks instead of in the perineural injection, Maagaard et al. discovered that dexamethasone improved the duration of analgesia of popliteal and saphenous nerve blocks in patients undergoing foot and ankle surgeries with or without dexmedetomidine. These findings support the theory that dexmedetomidine's local effects at the site of the injection, as opposed to its systemic analgesic effects on α2 receptors in the central nervous system, may be predominantly responsible for its role as an adjunct in prolonging the effects of local anesthetics in peripheral nerve blocks. The theory is also supported by Brummett et al and their findings that the analgesic effects of dexmedetomidine as an adjunct could not be reversed by an α2 receptor antagonist given systemically.
This study aims to determine a safe and effective approach for using dexamethasone and dexmedetomidine in combination using low, non-weight based (NWB) doses of both adjuncts. The researchers plan to track the duration of the blocks for 7 days postoperatively as well as any unwanted side effects in the post-anesthesia care unit including: hypotension, bradycardia, oversedation, and respiratory depression. The research team will contact subjects by email and rely on daily participant surveys (REDCap Survey POD #0) submitted electronically to provide subjective feedback on block duration and postoperative pain for 7 days using the PROMIS pain scale within the survey. Participants will also report pain medication usage for the same time frame including both opioid and non-opioid medications. Side effects in the post anesthesia care unit (PACU) will be documented by PACU nurses using the POSS sedation scale and comparing vital signs such as heart rate and blood pressure at 15- and 30-minute intervals to pre-operation recordings. Subjects might receive a phone call reminder to complete the daily surveys after their surgery, or if the research team notices that they have not completed the surveys on time.
Preliminary data has been very promising. The investigator's facility has thus far declined the use of liposomal bupivacaine, which has limited the ability to offer the patients peripheral nerve blocks lasting greater than 24 hours. Therefore, to extend the length of our peripheral nerve blocks the research team added both 4 mg dexamethasone and 50 mcg dexmedetomidine to 30 ml of 0.5% ropivacaine for lower extremity blocks for patients that would benefit from a prolonged nerve block for postoperative pain. The roughly 31.5 ml solution is then split evenly between the popliteal and saphenous nerve blocks. The investigators observed that these blocks frequently extended the duration of the block to 2-5 days compared to the standard 20-24 hours normally observed with dexamethasone adjunct alone. Similarly, the exact same additives (4 mg dexamethasone and 50 mcg dexmedetomidine) have been added to 15 ml of 0.5% Ropivacaine for shoulder procedures with similar observations noted of increased duration. This posed a research question that the investigators wishe to investigate further that compares their usual practice of blocks with ropivacaine and dexamethasone alone to blocks utilizing both dexamethasone and dexmedetomidine as adjuncts. The investigators chose the dexmedetomidine dose in combination with their inclusion criteria of adults weighing more than 50 kg so that the patients in this study will not receive a dexmedetomidine adjunct dose that is greater than 1 mcg/kg.
For the initial research the investigators plan on recruiting patients who are undergoing foot and ankle surgery who are not expected to participate in weight-bearing physical rehabilitation immediately after surgery and that would benefit from a potential multi-day nerve block for primary pain management. The investigators also plan on recruiting patients undergoing extensive shoulder surgery such as total shoulder arthroplasty and rotator cuff repairs because these procedures tend to have higher observed post-operative pain associated and the patients are not expected to participate in active rehabilitation immediately after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ropivicaine peripheral nerve block solution with 4mg Dexamethasone adjunct
Drug: Ropivacaine with low, non weight based Dexamethasone additive
Ropivacaine local anesthetic solution with 4mg Dexamethasone AND 25mcg Dexmedetomidine added
Drug: Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks
Drug pages: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Low, non-weight based dose of Dexamethasone and Dexmedetomidine adjunct with Ropivacaine (local anesthetic) for use in peripheral nerve blocks to look for synergistic effects of the combination in extending the duration of the block while limiting any potential side effects of each additive.
Also known as: Dexamethasone and Dexmedetomidine
Drug pages: RopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Very accepted, standard peripheral nerve block with steroid adjunct solution used to increase the duration of local anesthetic by 4-6hrs.
Also known as: Ropivacaine and Dexamethasone
Peripheral Nerve Block Duration
Using automated daily emailed patient surveys to assess for the duration of the peripheral nerve block.
Time frame: 0-7 days
Post-operative pain scores
Postoperative pain scores based on the Patient-Reported Outcomes Measurement Information System (PROMIS) numeric rating scale for pain intensity with response scores from 0 (no pain) to 10 (pain as bad as it can be) are to be reported daily by the participant for 7 days after surgery. Therefore, a higher score on the scale would indicate a worse outcome in terms of pain experienced by the participant.
Time frame: 0-7 days
Pain medicine (opioid and non-opioid) consumption post-operatively
Opioid and non-opioid pain medication consumption postoperatively, reported daily by the participant for 7 days
Time frame: 0-7 days
Post-opertive side effects
Measuring any reduction in opioid use side effects in the study group as a result of increased block duration leading to less opioid use for breakthrough pain. These side effects measured include: nausea, vomiting, lightheadedness, dizziness, and constipation.
Time frame: 0-7 days
Plan to share: Yes — Clinical researchers may contact the principal investigator (Ronald Tang, MD) to request the raw data for the study. All shared data will be void of personal identifiers. Sharing of data will be granted on a case by case basis determined by the credentials of the requesting researcher and necessity for requesting the data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 3 months and ending 3 years after the publication of results.
Access criteria: Researchers studying the effects of Dexmedetomidine and Dexamethasone may request access to the IPD and supporting information. The principal investigator will ultimately decide if criteria is met for data to be shared. In addition, a data sharing agreement may need to be signed on accordance with the University of Arizona and Banner University Medical Center policies.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Dexmedetomidine · Ropivacaine